1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Azilect (Parkinson’s Disease) - Forecast and Market Analysis to 2022

Azilect (Parkinson’s Disease) - Forecast and Market Analysis to 2022

  • March 2014
  • -
  • GlobalData
  • -
  • 61 pages

Summary

Table of Contents

Azilect (Parkinson’s Disease) - Forecast and Market Analysis to 2022

Summary

Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Azilect (rasagiline) is a second-generation MAO-B inhibitor, developed by Teva Pharmaceuticals for the treatment of the signs and symptoms of Parkinson’s disease. Azilect is approved for use as a monotherapy in early Parkinson’s disease at a once-daily dosage of 1mg, or as an adjunctive therapy to levodopa at 0.5mg or 1mg, as needed, once daily (Azilect package insert, 2012).

Scope

- Overview of Parkinson’s disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Azilect including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Azilect for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Brazil.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Parkinson’s disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Azilect performance
- Obtain sales forecast for Azilect from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Brazil).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Schizophrenia - Market Insights, Epidemiology and Market Forecast-2023

Schizophrenia - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Schizophrenia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Schizophrenia for the seven majo ...

Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases

Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases

  • $ 4950
  • Industry report
  • April 2017
  • by Frost & Sullivan

Disease-Modifying Treatments Likely to Transform the Clinical Management of Alzheimer’s and Parkinson’s Diseases The research service primarily encompasses comprehensive analyses of key emerging therapies ...

Schizophrenia - Epidemiology Forecast To 2023

Schizophrenia - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Schizophrenia - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Schizophrenia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.